Back to Agenda
Unraveling Evidence-Based Medicine: A Scientific, Ethical, and Socio-Political Analysis
Session Chair(s)
Christopher Marrone, PHARMD, RPH
Outcomes Liaison Advisor – National Accounts, Value, Evidence and Outcomes (VEO), Eli Lilly and Company, United States
There is concern worldwide about rising health costs and shrinking health budgets, and it is now broadly accepted that we must all apply the best alternatives in medical treatment. But disagreement persists as to what methods are acceptable for comparing treatments, and whether they are ethically, politically, and commercially sound. Some of the scientific and ethical questions will be addressed in this important cross-discipline community dialogue.
This forum has been developed by the DIA Evidence Based Medicine Community, the DIA Ethics and the Medicines Lifecycle Community, and the Comparative Effectiveness Scientific Working Group.
Learning Objective : Define evidence-based medicine; Explain the shift towards comparative effectiveness research; Discuss the key ethical, socio-political, and commercial implications of this shift.
Speaker(s)
Wendy Louise Lipworth
Senior Research Fellow, Centre for Values, Ethics and the Law in Medicine, University of Sydney, Australia
Panelist
Kitty Rajagopalan, PHD, MS
Vice President, Health Economics and Outcomes Research, Sunovion Pharmaceuticals Inc., United States
Panelist
Lisa M. Hess, PHD
Principal Research Scientist, US Health Outcomes, Eli Lilly and Company, United States
Panelist
Have an account?